STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVKD
  4. [Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cadrenal Therapeutics director and CEO Quang Pham reported open-market stock sales under a pre-set trading plan. He sold 9,167 shares of common stock on June 22, 2026 at a weighted average price of $3.55 per share and 2,277 shares on June 23, 2026 at a weighted average price of $3.20 per share, totaling 11,444 shares sold. These transactions were executed pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025. After the sales, he held 117,145 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

Positive

  • None.

Negative

  • None.

Insights

CEO Quang Pham sold 11,444 Cadrenal shares under a pre-set Rule 10b5-1 plan while retaining substantial direct and trust holdings.

The filing shows two open-market sales of Cadrenal Therapeutics common stock by Chairman, CEO and Interim CFO Quang Pham, totaling 11,444 shares at weighted average prices of $3.55 and $3.20 per share. These are classified as non-derivative, open-market transactions.

Footnotes state the sales were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025, indicating they were pre-planned rather than timed discretionarily. Following the trades, Pham holds 117,145 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.

The net effect is a net-sell of 11,444 shares with no derivative exercises and no gifts or tax-driven dispositions. Given the remaining direct and trust positions and the pre-arranged plan, these transactions appear routine from a governance perspective, with limited informational value about management’s current view of the stock.

Insider Pham Quang X
Role Chairman, CEO and Interim CFO
Sold 11,444 shs ($40K)
Type Security Shares Price Value
Sale Common Stock 2,277 $3.20 $7K
Sale Common Stock 9,167 $3.55 $33K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 117,145 shares (Direct, null); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)
Footnotes (1)
  1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 through $3.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 through $3.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
Shares sold total 11,444 shares Net shares sold across June 22–23, 2026
Sale price June 22, 2026 $3.55/share Weighted average sale price for 9,167 shares
Sale price June 23, 2026 $3.20/share Weighted average sale price for 2,277 shares
Direct holdings after sales 117,145 shares Common stock held directly by Quang Pham
Indirect trust holdings 200,000 shares Common stock held via The PVBQ Living Trust
Net buy/sell direction net-sell of 11,444 shares Transaction summary for this Form 4
Rule 10b5-1 trading arrangement regulatory
"shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
non-derivative financial
"transaction_type": "non-derivative""
The PVBQ Living Trust financial
"The PVBQ Living Trust and has sole voting and dispositive power"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pham Quang X
(Last)(First)(Middle)
C/O CADRENAL THERAPEUTICS, INC.
822 A1A NORTH, SUITE 306
(Street)
PONTE VEDRA FLORIDA 32082
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chairman, CEO and Interim CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026S9,167(1)D$3.55(2)119,422D
Common Stock06/23/2026S2,277(1)D$3.2(3)117,145D
Common Stock200,000IThe PVBQ Living Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 through $3.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 through $3.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Quang X. Pham06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CVKD CEO Quang Pham report in this Form 4?

Quang Pham reported selling 11,444 shares of Cadrenal Therapeutics common stock in two open-market transactions at weighted average prices of $3.55 and $3.20 per share, according to the Form 4 insider trading report.

Were Quang Pham’s Cadrenal (CVKD) stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the shares sold by Quang Pham were transacted under a Rule 10b5-1 trading arrangement that he adopted on September 25, 2025, indicating the sale schedule was pre-established in advance.

How many Cadrenal Therapeutics (CVKD) shares does Quang Pham hold after these sales?

After the reported sales, Quang Pham holds 117,145 shares directly. The Form 4 also shows 200,000 shares held indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power over the trust’s shares.

What were the sale prices for Quang Pham’s CVKD stock transactions?

On June 22, 2026, Quang Pham sold 9,167 shares at a weighted average price of $3.55, with individual trades ranging from $3.51 to $3.62. On June 23, 2026, he sold 2,277 shares at a weighted average price of $3.20.

Does Quang Pham have indirect ownership of Cadrenal (CVKD) shares through a trust?

Yes. The Form 4 shows 200,000 shares of Cadrenal Therapeutics common stock held indirectly through The PVBQ Living Trust. A footnote states he is trustee with sole voting and dispositive power, while his child is the sole beneficiary.

Did the Form 4 for CVKD report any option exercises or derivative transactions?

No. The transaction summary indicates no derivative exercises or derivative transactions. All reported activity involves non-derivative common stock sales and a separate line reflecting indirect holdings through The PVBQ Living Trust.